StreetInsider.com News Articles

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 04 Mar 2026 07:00:00 -0500

RESEARCH TRIANGLE PARK, N.C., March 04, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the compensation committee of BioCryst’s board of directors granted six newly-hired employees restricted stock units (RSUs) covering an aggregate of 65,850 shares of BioCryst common stock. The RSUs were granted as of March 2, 2026, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date,

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 04 Mar 2026 07:00:00 -0500

The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date,

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 04 Mar 2026 07:00:00 -0500

The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date,

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 04 Mar 2026 07:00:00 -0500

The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date,

Form 4 BIOCRYST PHARMACEUTICALS For: Feb 27 Filed by: Milne Jill C.

Tue, 03 Mar 2026 16:41:00 -0500

si-local-file:///var/storage/secattach/20260303/26102473.html

Form 4 BIOCRYST PHARMACEUTICALS For: Feb 27 Filed by: Milne Jill C.

Tue, 03 Mar 2026 16:41:00 -0500

si-local-file:///var/storage/secattach/20260303/26102473.html

Form 4 BIOCRYST PHARMACEUTICALS For: Feb 27 Filed by: Stonehouse Jon P

Tue, 03 Mar 2026 16:39:00 -0500

si-local-file:///var/storage/secattach/20260303/26102373.html

Form 4 BIOCRYST PHARMACEUTICALS For: Feb 27 Filed by: Stonehouse Jon P

Tue, 03 Mar 2026 16:39:00 -0500

si-local-file:///var/storage/secattach/20260303/26102373.html

Form 4 BIOCRYST PHARMACEUTICALS For: Feb 27 Filed by: MILANO VINCENT

Tue, 03 Mar 2026 16:36:00 -0500

si-local-file:///var/storage/secattach/20260303/26102251.html

Form 4 BIOCRYST PHARMACEUTICALS For: Feb 27 Filed by: MILANO VINCENT

Tue, 03 Mar 2026 16:36:00 -0500

si-local-file:///var/storage/secattach/20260303/26102251.html

Form 4 BIOCRYST PHARMACEUTICALS For: Feb 27 Filed by: Frank Steven

Tue, 03 Mar 2026 16:33:00 -0500

si-local-file:///var/storage/secattach/20260303/26102144.html

Form 4 BIOCRYST PHARMACEUTICALS For: Feb 27 Filed by: Frank Steven

Tue, 03 Mar 2026 16:33:00 -0500

si-local-file:///var/storage/secattach/20260303/26102144.html

Form 4 BIOCRYST PHARMACEUTICALS For: Feb 27 Filed by: McKee Amy E

Tue, 03 Mar 2026 16:29:00 -0500

si-local-file:///var/storage/secattach/20260303/26102014.html

Form 4 BIOCRYST PHARMACEUTICALS For: Feb 27 Filed by: McKee Amy E

Tue, 03 Mar 2026 16:29:00 -0500

si-local-file:///var/storage/secattach/20260303/26102014.html

Form 144 BIOCRYST PHARMACEUTICALS Filed by: Stonehouse Jon P

Mon, 02 Mar 2026 15:16:00 -0500

si-local-file:///var/storage/secattach/20260302/26091376.html

Form 144 BIOCRYST PHARMACEUTICALS Filed by: Stonehouse Jon P

Mon, 02 Mar 2026 15:16:00 -0500

si-local-file:///var/storage/secattach/20260302/26091376.html

Form 10-K BIOCRYST PHARMACEUTICALS For: Dec 31

Thu, 26 Feb 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260226/26070472.html

Form 10-K BIOCRYST PHARMACEUTICALS For: Dec 31

Thu, 26 Feb 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260226/26070472.html

TD Cowen Reiterates Buy Rating on BioCryst Pharma (BCRX)

Thu, 26 Feb 2026 13:30:45 -0500

TD Cowen analyst Stacy Ku reiterated a Buy rating and $30.00 price target on BioCryst Pharma (NASDAQ: BCRX).

The analyst comments "Q4 Orladeyo reached $151MM (+3% Q/Q), in line with pre-announcement. For 2026,mgmt reiterated rev guidance of $625-645MM (+11-15%), which reflects +12%Y/Ygrowth for US sales, driven by still steady patient accumulation, solid retention despitenew injectable entrants, and the pediatric expansion. Orladeyo & navenibart eachrepresent $1B peak drugs & solidifies BCRX's position in HAE."

For an analyst ratings summary and ratings history on BioCryst Pharma click here. For more ratings news on BioCryst Pharma click here.

Shares of BioCryst Pharma closed at

BioCryst Pharma (BCRX) Tops Q4 EPS by 108c; offers outlook

Thu, 26 Feb 2026 07:58:11 -0500

BioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of $1.12, $1.08 better than the analyst estimate of $0.04. Revenue for the quarter came in at $406.55 million versus the consensus estimate of $150.06 million.

Financial Outlook for 2026
The company maintained its expectation for full year 2026 global net ORLADEYO revenue to be between $625 million and $645 million and for full year 2026 total revenue, including RAPIVAB® (peramivir injection), to be between $635 million and $660 million.

The company also maintained its expectation for full year 2026 non-GAAP operating expenses, excluding stock-based compensation, restructuring, and transaction-related costs, to be between $450 million

Form 8-K BIOCRYST PHARMACEUTICALS For: Feb 26

Thu, 26 Feb 2026 07:20:00 -0500

si-local-file:///var/storage/secattach/20260226/26064373.html

Form 8-K BIOCRYST PHARMACEUTICALS For: Feb 26

Thu, 26 Feb 2026 07:20:00 -0500

si-local-file:///var/storage/secattach/20260226/26064373.html

BioCryst Reports Full Year 2025 Financial Results and Provides Business Update

Thu, 26 Feb 2026 07:00:00 -0500

—Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A. on October 1, 2025)—

—Record GAAP and non-GAAP operating profit for full year 2025—

—Maintained full year 2026 ORLADEYO revenue guidance between $625 and $645 million—

—Received FDA approval for ORLADEYO oral pellets for patients with HAE Aged 2 to <12 Years—

—Completed Acquisition of Astria Therapeutics—

RESEARCH TRIANGLE PARK, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) --

BioCryst Reports Full Year 2025 Financial Results and Provides Business Update

Thu, 26 Feb 2026 07:00:00 -0500

—Record GAAP and non-GAAP operating profit for full year 2025—

—Maintained full year 2026 ORLADEYO revenue guidance between $625 and $645 million—

—Received FDA approval for ORLADEYO oral pellets for patients with HAE Aged 2 to <12 Years—

—Completed Acquisition of Astria Therapeutics—

RESEARCH TRIANGLE PARK, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) --

BioCryst Reports Full Year 2025 Financial Results and Provides Business Update

Thu, 26 Feb 2026 07:00:00 -0500

—Record GAAP and non-GAAP operating profit for full year 2025—

—Maintained full year 2026 ORLADEYO revenue guidance between $625 and $645 million—

—Received FDA approval for ORLADEYO oral pellets for patients with HAE Aged 2 to <12 Years—

—Completed Acquisition of Astria Therapeutics—

RESEARCH TRIANGLE PARK, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) --